stock-detail (CCXI)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 06:17 pm

4/24/2017 06:17 pm

4/24/2017 06:17 pm

4/24/2017 06:17 pm

4/20/2017 12:17 pm

4/20/2017 06:17 am

4/9/2017 06:17 am

ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)

3/22/2017 12:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., March 22, 2017-- ChemoCentryx, Inc.,, a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the ...

ChemoCentryx reports 4Q loss

3/14/2017 09:00 pm

ChemoCentryx reports 4Q loss

3/14/2017 09:00 pm

ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results

3/14/2017 08:00 pm

[GlobeNewswire] - --Expanded Vifor Pharma partnership now totals $155 million in upfront cash commitments, $1.2 billion in potential milestone payments, plus substantial royalties on potential net sales--. --Initiated Phase ...

ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017

3/1/2017 01:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., March 01, 2017-- ChemoCentryx, Inc.,, today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017. ChemoCentryx ...

ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference

2/28/2017 01:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., Feb. 28, 2017-- ChemoCentryx, Inc.,, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health ...